Compositions and methods are provided for treating advanced clear cell renal cell carcinoma (RCC) in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6, in combination with a therapeutic dose of cabozantinib.

A method for producing a professional antigen-presenting cell, including inducing expression of c-MYC, BMI1, and MDM2 in a myeloid cell (MC) to obtain a proliferative myeloid cell (pMC), and inducing expression of GM-CSF and/or M-CSF in the pMC to obtain a professional antigen-presenting cell (pAPC). The myeloid cell is a myeloid cell differentiated from a pluripotent stem cell.

A peptide is disclosed that has an amino acid sequence selected from X.sub.1-X.sub.2-X.sub.3-Gln-Leu-Met-Leu-Cys-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 3), X.sub.1-X.sub.2-X.sub.3-Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 4), Ile-Ser-Phe-Gln-Leu-Met-Leu (SEQ ID NO: 5), Leu-Cys-Val-Leu-Asp-Tyr-Phe (SEQ ID NO: 6), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 10), Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11 (SEQ ID NO: 11), Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu (SEQ ID NO: 12), X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu (SEQ ID NO: 13), Asp-Leu-Val-Ile-Ser-Phe-Gln-Leu-Met-Leu-Cys-Val-Leu-Asp-Tyr-Phe-Ile-Lys (SEQ ID NO: 14) and retro-inverso peptides thereof. The peptides disclosed herein may be used to treat liver cancer, lung cancer, breast cancer, pancreatic cancer, or brain cancer.

A peptide is disclosed that has an amino acid sequence selected from X.sub.1-X.sub.2-X.sub.3-Gln-Leu-Met-Leu-Cys-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 3), X.sub.1-X.sub.2-X.sub.3-Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 4), Ile-Ser-Phe-Gln-Leu-Met-Leu (SEQ ID NO: 5), Leu-Cys-Val-Leu-Asp-Tyr-Phe (SEQ ID NO: 6), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 7), X.sub.1-X.sub.2-X.sub.3-X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu-X.sub.4-X.sub.5-X.sub.6 (SEQ ID NO: 10), Gln-X.sub.7-Met-X.sub.10-Cys-Val-X.sub.11 (SEQ ID NO: 11), Gln-Leu-X.sub.8-Leu-X.sub.9-Val-Leu (SEQ ID NO: 12), X.sub.12-Leu-Met-Leu-Cys-X.sub.13-Leu (SEQ ID NO: 13), Asp-Leu-Val-Ile-Ser-Phe-Gln-Leu-Met-Leu-Cys-Val-Leu-Asp-Tyr-Phe-Ile-Lys (SEQ ID NO: 14) and retro-inverso peptides thereof. The peptides disclosed herein may be used to treat liver cancer, lung cancer, breast cancer, pancreatic cancer, or brain cancer.

The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.

The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.

The invention provides compositions and methods for binding Ras in a nucleotide free state (apo RAS) and inhibiting Ras signaling. In one embodiment, the invention provides monobodies that specifically bind apo RAS and methods of use. Thus, in diseases and conditions where a reduction of Ras signaling is beneficial, such inhibitory compositions act as therapeutics.

Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The invention provides highly potent and stable peptide mimetics of human DKK3b having numerous improved properties. The peptide mimetics of the invention are useful as therapeutics in the treatment of various diseases wherein inhibiting nuclear translocation of β-catenin is therapeutic, including, but not limited to, cancer/proliferative, metabolic, osteoporosis, neurological, immunological, endocrinologic, cardiovascular, hematologic, and inflammatory diseases.